


IN THE CLAIMS

Claims 1-21 (canceled)

22. (currently amended) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises administering to the host effective amounts of:

- (a) an interferon, and
- (b) at least one compound selected from the group consisting of:
 - 5-membered cyclic nucleosides having the formula (I):




RECEIVED

NOV 05 2003

TECH CENTER 1600/2900


wherein $[[*X*]] - X -$ is $=CH-$, $-CH_2-$ or $-O-$, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II):




wherein R_4 is $-OR_6$ or $-N(R_7)R_8$ in which R_6 , R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1 - C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1 - C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):




wherein R_9 is a hydrogen atom or




wherein R_{10} is a hydrogen atom, C_1 - C_6 alkyl, hydroxy(C_1 - C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} and R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN , and pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):




wherein each of R_{14} , R_{15} , R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1-C_6) alkyl, (C_6-C_{10}) aryl and (C_7-C_{18}) aralkyl; and

2,4-diaminopyrimidines having the formula (V):



wherein R_{20} is phenyl substituted by one or more substituents selected from the group consisting of benzyl, NO_2 , (C_1-C_6) alkylamino and halogen and R_{21} is H or C_1-C_6 alkyl; or R_{20} and R_{21} form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



wherein Z is $-CH_2NR_{23}-$ or $-NR_{23}CH_2-$; R_{22} , R_{23} and R_{24} are each, independently, H or C_1-C_6 alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

23. (previously presented) A method according to claim 22, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis

encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

24. (previously presented) A method according to claim 22, wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

25. (previously presented) A method according to claim 22, wherein the interferon (a) is a human interferon.

26. (previously presented) A method according to claim 22, wherein the interferon is selected from interferon $\alpha 2$, interferon $\alpha 8$ and interferon β .

27. (previously presented) A method according to claim 26, wherein the interferon is human interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg protein.

28. (previously presented) A method according to claim 26, wherein the interferon is human interferon β having a specific activity of from 4×10^8 to 8×10^8 per mg protein.

29. (currently amended) A method according to claim 22, wherein the compound (b) is at least one compound selected from the group consisting of cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1- β -D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine, aristeromycin, pyrazofurin, tiazaforin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.

30. (withdrawn) Products containing an interferon and at least one compound (b) as defined in claim 22 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.

Claims 31-37 (canceled)

38. (previously presented) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic antiviral or antirhabdoviral effect, an interferon and at least one compound (b) as defined in claim 22.

39. (withdrawn) An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 22.